The first large prospective study of 136 patients across 13 institutions receiving SMART for pancreatic cancer achieved local control in 83% and distant control in 51% of patients at one year with 3 patients experiencing grade 3+ toxicity.
Citation(s)
- Parikh, ASTRO 2022